# Market Madness: Reverse Splits and Wild Dreams! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-09-17T14:01:00.483Z Source: https://newsyai.com/edition/7a742987-5c30-4244-87b9-5a5a6b619dba Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Market Mayhem: Reverse-Split Roulette 23.5 – Jaguar Diarrhea Dreams, Cannabis-to-Trafalgar Pivot Porn & E-Power Battery Boners (September 17, 2026 Edition!)** Futures mixed (Dow flatter than a serial reverse-splitter’s promise, Nasdaq still AI/chip-humping like it’s 2025 forever, crude oil grinding like a desperate microcap CEO begging for another raise). MVLS drama paused, but the microcap reverse-split parade marches on with fresh meat: Jaguar Health’s plant-based poop meds chasing Nasdaq survival, Greater Cannabis rebranding from weed dreams to Trafalgar “international” whatever after a hostile-ish takeover and debt wipe, and E-Power’s China battery plays dodging bid-price bullets with a 25-for-1 coming tomorrow. Yesterday’s shrimp farmers, shipping degens, and AI wellness wet dreams? Old news. Bulls scream “shrunken float + any catalyst = degen rip”; bears smell serial dilution, cash bonfires, execution flops, lawsuit ghosts, and delisting specters.[[1]](https://www.stocktitan.net/news/stock-split-calendar) ### 1) JAGX (Jaguar Health, Inc.): “1-for-15 Poop Stiffy vs. Crofelemer MVID Miracles & Chronic Dilution Diarrhea” **Why it’s loud** 1-for-15 reverse split effective Sept 17 for Nasdaq compliance after repeated bid-price woes (part of a long history of splits). Focus on Crofelemer (plant-based) for microvillus inclusion disease (MVID) with intestinal failure, plus animal health (Canalevia for dog chemo diarrhea). Recent dilution via note conversions, preferred stock retirements, and more shares issued.[[2]](https://www.sec.gov/Archives/edgar/data/1585608/000119312526391415/0001193125-26-391415.txt) **Bull case (poop boner + compliance rocket)** Compressed float + “exploding rare disease and gut-health tailwinds” = quick rip on any MVID trial data, NDA filing (target mid-2027?), partnership, or sector hype. Ride the post-split pop, degens—real unmet medical needs could fuel a spicy squeeze before the next raise! **Bear case (poop limp dick & dilution tsunami)** Chronic cash burn, repeated compliance desperation, massive dilution history, and tiny market cap scream dilution graveyard; brutal execution risks in clinical trials and macro misses = sub-penny fade after any hype pop. Short the fade before the next offering or data miss! **My take, first principles (real biotech signal vs. listing cancer)** Rare-disease gut meds address legitimate unmet needs (people shit, and some can’t stop), but repeated split gymnastics, cash pressures, and dilution point to short-term pop on split/news rather than durable fundamentals. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.15–2.00** range, **$0.60C** trial/partnership pump—**P$0.15** dilution fade. ### 2) GCAN (Greater Cannabis Co / Trafalgar International): “1-for-5 Weed Stiffy vs. Trafalgar Rebrand Dreams & Debt-Clean Pivot Nightmares” **Why it’s loud** 1-for-5 reverse split effective Sept 17 for (presumed) compliance/OTC vibes. Former cannabis play that just underwent massive change in control (Trafalgar Asset Management taking ~96.6% voting power via preferreds), debt cancellations turning it profitable on paper, leadership overhaul, and rebrand to Trafalgar International (pivoting toward financial services/tech/IP). Tiny market cap, pre-revenue core ops.[[3]](https://www.tipranks.com/news/company-announcements/greater-cannabis-undergoes-leadership-change-and-debt-restructuring) **Bull case (weed boner + compliance rocket)** Compressed float + “new controlling shareholder + clean balance sheet + pivot tailwinds” = quick rip on any rebrand hype, new deals, or sector momentum. Ride the post-split pop, degens—real demand for whatever Trafalgar becomes could spark a degen squeeze! **Bear case (weed limp dick & dilution tsunami)** Pre-revenue history, going-concern flags, pivot execution risks, and microcap governance drama scream dilution hell; volatile OTC trading and funding misses = sub-penny graveyard after any hype pop. Short the fade before the next raise or pivot flop! **My take, first principles (real pivot signal vs. listing cancer)** Cannabis-to-international rebrand taps legitimate “new management cleans house” narratives, but repeated compliance fixes, tiny scale, and pivot history point to short-term pop on split/news rather than durable fundamentals. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.20–2.50** range, **$0.80C** rebrand/deal pump—**P$0.20** dilution fade. ### 3) EPOW (E-Power Inc.): “1-for-25 Battery Stiffy vs. China Anode & Charging Station Boners & Compliance Desperation” **Why it’s loud** 1-for-25 reverse split effective Sept 18 for Nasdaq compliance after bid-price deficiency (cure period into Nov). Battery anode materials (graphite/silicon-carbon for EVs), recent big China contracts (RMB 343M turnkey), Azusa CA mega-charging station negotiations, and AI data center microgrid plays. Classic China microcap with funding and execution questions.[[4]](https://www.stocktitan.net/sec-filings/EPOW/6-k-e-power-inc-current-report-foreign-issuer-379ace6720e8.html) **Bull case (battery boner + compliance rocket)** Compressed float + “EV/AI data center energy tailwinds in exploding global markets” = quick rip on any contract close, partnership, or sector hype. Ride the post-split pop, degens—real battery demand could fuel a spicy squeeze! **Bear case (battery limp dick & dilution tsunami)** Cash burn/China risks, competition/execution challenges, and compliance desperation scream dilution graveyard; volatile geopolitics and funding misses = sub-penny fade after any hype pop. Short the fade before the next raise or contract miss! **My take, first principles (real energy signal vs. listing cancer)** Battery materials and charging infrastructure address legitimate EV/AI power needs (the world needs electrons), but repeated split gymnastics, cash pressures, and China exposure point to short-term pop on split/news rather than durable fundamentals. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.12–1.60** range, **$0.45C** contract/hype pump—**P$0.12** dilution fade. **Tape-Side Tactics (JAGX Poop Docs, GCAN Trafalgar Degens & EPOW Battery Chargers – September 17 Edition)** - **JAGX**: **$0.15–2.00** stiffy; **$0.60C** trial/partnership pump, **P$0.15** dilution fade. - **GCAN**: **$0.20–2.50** stiffy; **$0.80C** rebrand/deal pump, **P$0.20** dilution fade. - **EPOW**: **$0.12–1.60** stiffy; **$0.45C** contract/hype pump, **P$0.12** dilution fade. MVLS pressure paused but the reverse-split addiction still tightening the noose amid AI hype and micro-madness. Balls-deep DYOR, NFA, degens—duck the dilutions! **Sources** (for tracking every claim above): - Reverse splits & calendars: Stock Titan, TipRanks, GlobeNewswire, Seeking Alpha, SEC filings (Sep 2026 data). - Company context & filings: Recent 6-K/8-K/10-Q announcements via Stock Titan/SEC (JAGX split & dilution notes, GCAN control/rebrand/debt details, EPOW split & contract updates). - Broader microcap/premarket context & volatility: Yahoo Finance, company IR pages, Seeking Alpha.